➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
McKesson
Merck
Express Scripts

Last Updated: October 27, 2021

57 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2021 - 2022

Loss of Exclusivity / End of Market Exclusivity Period dates

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "57 Drugs Facing NCE-1 / Abbreviated New Drug Application acceptance dates in 2021 - 2022" DrugPatentWatch.com thinkBiotech, 2021 www.drugpatentwatch.com/p/nce-1/.
Media collateral
These NCE-1 dates indicate the first opportunity for generic drug companies to file Abbreviated New Drug Applications (ANDAs) for generic entry into branded drug markets. Generic launch is dependent on many factors, including FDA approval and patents. This information is provided as a rough estimate of generic application, and does not indicate when generics will launch. For more information see the complete DrugPatentWatch database.
When can drug patent challenges be filed against CALQUENCE?

Generic name: acalabrutinib
NCE-1 Date: October 2021

CALQUENCE is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has one hundred and thirty-one patent family members in forty-six countries. There has been litigation on patents covering CALQUENCE

See drug price trends for CALQUENCE.

The generic ingredient in CALQUENCE is acalabrutinib. Additional details are available on the acalabrutinib profile page.

When can drug patent challenges be filed against ROCKLATAN?

Generic name: latanoprost; netarsudil dimesylate
NCE-1 Date: December 2021

Drug Price Trends for ROCKLATAN
ROCKLATAN is a drug marketed by Aerie Pharms Inc. There are thirteen patents protecting this drug.

This drug has fifty-eight patent family members in nine countries.

See drug price trends for ROCKLATAN.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this API. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

When can drug patent challenges be filed against SEGLUROMET?

Generic name: ertugliflozin; metformin hydrochloride
NCE-1 Date: December 2021

Drug Price Trends for SEGLUROMET
SEGLUROMET is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-four patent family members in forty-eight countries.

See drug price trends for SEGLUROMET.

The generic ingredient in SEGLUROMET is ertugliflozin; metformin hydrochloride. Additional details are available on the ertugliflozin; metformin hydrochloride profile page.

When can drug patent challenges be filed against STEGLUJAN?

Generic name: ertugliflozin; sitagliptin phosphate
NCE-1 Date: December 2021

Drug Price Trends for STEGLUJAN
STEGLUJAN is a drug marketed by Merck Sharp Dohme. There are five patents protecting this drug.

This drug has two hundred and ten patent family members in fifty-four countries. There has been litigation on patents covering STEGLUJAN

See drug price trends for STEGLUJAN.

The generic ingredient in STEGLUJAN is ertugliflozin; sitagliptin phosphate. Additional details are available on the ertugliflozin; sitagliptin phosphate profile page.

When can drug patent challenges be filed against GIAPREZA?

Generic name: angiotensin ii acetate
NCE-1 Date: December 2021

GIAPREZA is a drug marketed by La Jolla Pharma. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in twenty countries.

See drug price trends for GIAPREZA.

The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this API. Additional details are available on the angiotensin ii acetate profile page.

When can drug patent challenges be filed against LUTATHERA?

Generic name: lutetium dotatate lu-177
NCE-1 Date: January 2022

LUTATHERA is a drug marketed by Aaa Usa Inc. There are two patents protecting this drug.

This drug has eighteen patent family members in eleven countries. There has been litigation on patents covering LUTATHERA

See drug price trends for LUTATHERA.

The generic ingredient in LUTATHERA is lutetium dotatate lu-177. There are four drug master file entries for this API. Additional details are available on the lutetium dotatate lu-177 profile page.

When can drug patent challenges be filed against BIKTARVY?

Generic name: bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate
NCE-1 Date: February 2022

Drug Price Trends for BIKTARVY
BIKTARVY is a drug marketed by Gilead Sciences Inc. There are ten patents protecting this drug.

This drug has five hundred and one patent family members in sixty-four countries. There has been litigation on patents covering BIKTARVY

See drug price trends for BIKTARVY.

The generic ingredient in BIKTARVY is bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate. Additional details are available on the bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate profile page.

When can drug patent challenges be filed against SYMDEKO (COPACKAGED)?

Generic name: ivacaftor; ivacaftor, tezacaftor
NCE-1 Date: February 2022

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.

This drug has three hundred and eighty patent family members in thirty-seven countries.

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can drug patent challenges be filed against TRIKAFTA (COPACKAGED)?

Generic name: elexacaftor, ivacaftor, tezacaftor; ivacaftor
NCE-1 Date: February 2022

TRIKAFTA (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-one patents protecting this drug.

This drug has four hundred and nine patent family members in forty-two countries.

The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.

When can drug patent challenges be filed against AKYNZEO?

Generic name: fosnetupitant chloride hydrochloride; palonosetron hydrochloride
NCE-1 Date: April 2022

AKYNZEO is a drug marketed by Helsinn Hlthcare. There are eighteen patents protecting this drug.

This drug has two hundred and fifty-six patent family members in sixty-eight countries.

See drug price trends for AKYNZEO.

The generic ingredient in AKYNZEO is fosnetupitant chloride hydrochloride; palonosetron hydrochloride. There is one drug master file entry for this API. Additional details are available on the fosnetupitant chloride hydrochloride; palonosetron hydrochloride profile page.

When can drug patent challenges be filed against LOKELMA?

Generic name: sodium zirconium cyclosilicate
NCE-1 Date: May 2022

Drug Price Trends for LOKELMA
LOKELMA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug.

This drug has one hundred and eighteen patent family members in thirty-four countries.

See drug price trends for LOKELMA.

The generic ingredient in LOKELMA is sodium zirconium cyclosilicate. There are one thousand four hundred and seventy-two drug master file entries for this API. Additional details are available on the sodium zirconium cyclosilicate profile page.

When can drug patent challenges be filed against ORIAHNN (COPACKAGED)?

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
NCE-1 Date: July 2022

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are seven patents protecting this drug.

This drug has fifty-five patent family members in twenty-four countries.

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

When can drug patent challenges be filed against OMEGAVEN?

Generic name: fish oil triglycerides
NCE-1 Date: July 2022

OMEGAVEN is a drug marketed by Fresenius Kabi Usa. There are three patents protecting this drug.

This drug has five patent family members in four countries. There has been litigation on patents covering OMEGAVEN

See drug price trends for OMEGAVEN.

The generic ingredient in OMEGAVEN is fish oil triglycerides. There are six drug master file entries for this API. Additional details are available on the fish oil triglycerides profile page.

When can drug patent challenges be filed against ANNOVERA?

Generic name: ethinyl estradiol; segesterone acetate
NCE-1 Date: August 2022

ANNOVERA is a drug marketed by Therapeuticsmd Inc. There are six patents protecting this drug.

This drug has one patent family member in one country.

See drug price trends for ANNOVERA.

The generic ingredient in ANNOVERA is ethinyl estradiol; segesterone acetate. There are twenty-six drug master file entries for this API. Additional details are available on the ethinyl estradiol; segesterone acetate profile page.

When can drug patent challenges be filed against ONPATTRO?

Generic name: patisiran sodium
NCE-1 Date: August 2022

ONPATTRO is a drug marketed by Alnylam Pharms Inc. There are twenty-three patents protecting this drug.

This drug has four hundred and sixty-one patent family members in thirty-five countries. There has been litigation on patents covering ONPATTRO

See drug price trends for ONPATTRO.

The generic ingredient in ONPATTRO is patisiran sodium. Additional details are available on the patisiran sodium profile page.

When can drug patent challenges be filed against DELSTRIGO?

Generic name: doravirine; lamivudine; tenofovir disoproxil fumarate
NCE-1 Date: August 2022

DELSTRIGO is a drug marketed by Msd Merck Co. There are three patents protecting this drug.

This drug has eighty-one patent family members in forty-four countries.

The generic ingredient in DELSTRIGO is doravirine; lamivudine; tenofovir disoproxil fumarate. Additional details are available on the doravirine; lamivudine; tenofovir disoproxil fumarate profile page.

When can drug patent challenges be filed against EPIDIOLEX?

Generic name: cannabidiol
NCE-1 Date: September 2022

EPIDIOLEX is a drug marketed by Gw Res Ltd. There are seventeen patents protecting this drug.

This drug has one hundred and five patent family members in twenty-two countries. There has been litigation on patents covering EPIDIOLEX

See drug price trends for EPIDIOLEX.

The generic ingredient in EPIDIOLEX is cannabidiol. There are nine drug master file entries for this API. Additional details are available on the cannabidiol profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKinsey
Medtronic
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.